Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 14, 2014 (12 years ago)

Cyclobenzaprine HCI active pharmaceutical ingredient packaged in…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Cyclobenzaprine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada

Drug: Cyclobenzaprine

Recalling firm
Attix Pharmaceuticals
Origin
Canada
Initiated by
Voluntary: Firm initiated
FDA recall number
D-605-2015 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cyclobenzaprine recalls

See all
Class I · High risk

Cyclobenzaprine Hydrochloride Tablets

Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets USP, 10 mg 90-count tablets (blue in color).

Ongoing Labeling / mix-up Unichem Pharmaceuticals USA Inc. NDC 29300-415-19 D-0655-2025
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 57237-266-01 D-0776-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 70199-014-01 D-0775-2021
Class II · Moderate risk

Cyclobenzaprine Hydrochloride Tablets

CGMP Deviations: Out of specification (OOS) test result for Total Aerobic Microbial Count (TAMC) and Total Yeast and Mold Count (TYMC) for an excipient batch of Dibasic Calcium Phosphate.

Terminated Microbial contamination Teva Pharmaceuticals USA NDC 0591-3330-01 D-0774-2021

Other recalls by Attix Pharmaceuticals

All 2014 recalls
Class III · Low risk

Mycophenolate Mofetil

cGMP deviation; manufacturer is Not Registered with the Food and Drug Administration

Terminated cGMP deviation Attix Pharmaceuticals Inc D-1047-2016
Class II · Moderate risk

Zonisamide active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-960-2015
Class II · Moderate risk

Zolmitriptan active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-959-2015
Class II · Moderate risk

Zoledronic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-958-2015